To address this, we introduced a constitutively active TGFB1 construct into these cells, resulting in a 47.6‐fold upregulation of TGFB1 mRNA expression (Fig. 4C), prior to co‐injection with DCIS cells subcutaneously into recipient mice. The gene discussed is TGFB1; the disease is ductal breast carcinoma in situ.